Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE EBITDA Margin

EBITDA as a percentage of revenue.

Pfizer Inc.NYSE: PFE

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 10.9%

EBITDA Margin was 10.9% in Q2 FY2026, down 25.4 pp from a year earlier. On a trailing-twelve-month basis it was 21.2%, down 10.4 pp year over year. Over 3 fiscal years it narrowed by 13.7 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 48.5% for the fiscal year ending Dec 2026, up from 26.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
10.9%-26.8 pp QoQ
Last fiscal yearDec 2025
26.8%-1.7 pp YoY
LTMJun 2026
21.2%-10.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-25.4 pp+14.0 pp+39.4 pp
1 year-1.7 pp+21.6 pp+23.3 pp
3 years-13.7 pp+19.0 pp+32.7 pp
5 years+15.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
26.8%
Year-over-year change
-1.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PFE compares with its peers on the latest reported figures

  • PFE's LTM Jun 2026 EBITDA Margin of 21.2% is the 9th highest of the 11 companies compared; the peer median is 32.6%.
  • Its year-over-year change of -10.4 pp is the 8th highest of 11, against a peer median of -0.1 pp.
  • Over three fiscal years its change of -13.7 pp compares with a peer median of +7.9 pp.
PFE Competitors Peer median
EBITDA Margin for PFE and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202634.2% +2.6 pp-10.0 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
Peer median (excluding PFE) 32.6%-0.1 pp+7.9 pp

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.29B101.18B59.55B63.63B62.58B
Cost of Revenue30.82B34.34B24.95B17.85B16.07B
Gross Profit50.47B66.83B34.6B45.78B46.51B
Gross Margin62.1%66.1%58.1%71.9%74.3%
Research & Development13.83B11.43B10.68B10.82B10.44B
Selling, General & Admin12.7B13.68B14.77B14.73B13.79B
Operating Expenses30.23B28.71B30.18B30.84B29.11B
Depreciation & Amortization5.19B5.06B6.29B7.01B6.59B
EBITDA30.79B41.03B9.56B18.13B16.78B
EBITDA Margin37.9%40.6%16.0%28.5%26.8%
Operating Income20.24B38.12B4.42B14.94B17.41B
Operating Margin24.9%37.7%7.4%23.5%27.8%
Interest Income36M251M1.62B545M603M
Interest Expense1.29B1.24B2.21B3.09B2.67B
Other Income / Expenses4.08B(3.39B)(3.36B)(6.92B)(9.89B)
Income Before Tax24.31B34.73B1.06B8.02B7.52B
Pre-Tax Margin29.9%34.3%1.8%12.6%12.0%
Income Tax Expense1.85B3.33B(1.12B)(28M)(266M)
Net Income21.98B31.37B2.12B8.03B7.77B
Net Margin27.0%31.0%3.6%12.6%12.4%
EPS (Basic)3.955.590.381.421.36
EPS (Diluted)3.885.470.371.411.36
Weighted Avg Shares5.6B5.61B5.64B5.66B5.68B
Weighted Avg Shares (Diluted)5.71B5.73B5.71B5.7B5.69B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.